We can’t show the full text here under this license. Use the link below to read it at the source.
Multi-omics analyses identify gut microbiota-fecal metabolites-brain-cognition pathways in the Alzheimer’s disease continuum
Gut bacteria and their metabolites linked to brain function and thinking in Alzheimer's disease stages
AI simplified
Abstract
Significant group differences in gut microbial composition were observed, driven by 8 microbial taxa that increased and 2 that decreased from healthy controls to Alzheimer's disease patients.
- Eight microbial taxa, including Staphylococcus and Bacillus, showed a progressive increase in relative abundance from healthy controls to mild cognitive impairment and Alzheimer's disease.
- Two taxa, such as Anaerostipes, demonstrated a gradual decrease in relative abundance across the same groups.
- A total of 26 fecal metabolites, including Arachidonic, Adrenic, and Lithocholic acids, exhibited a progressive increase from healthy controls to mild cognitive impairment and Alzheimer's disease.
- Progressive gray matter atrophy and damage to white matter integrity were observed in patients along the Alzheimer's disease continuum.
- Significant associations were found between gut microbiota, metabolites, neuroimaging measures, and cognitive variables.
- Two potential mediation pathways were identified: microbiota affecting metabolites, which in turn influence neuroimaging and cognition.
AI simplified
Key numbers
166
Participants
30 patients with AD, 75 individuals with MCI, and 61 healthy controls.
26
Fecal Metabolites
Metabolites increased from HC to MCI to AD.
8
Microbial Taxa
Taxa increased from HC to MCI to AD.